Intermediate vancomycin resistance in Staphylococcus aureus: A major threat or a minor inconvenience?

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 3, 1998, Pages 289-291

  Johnson, Alan P ^a  

^a CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN; CHLORAMPHENICOL; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; HABEKACIN; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE; VANCOMYCIN;

ABSCESS; ANTIBIOTIC RESISTANCE; BACTERIAL PERITONITIS; CASE REPORT; FRANCE; GRAM NEGATIVE BACTERIUM; HUMAN; JAPAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; SHORT SURVEY; STAPHYLOCOCCUS AUREUS; UNITED STATES;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0031659553     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.3.289     Document Type: Short Survey

References (19)

1. Payne, D. J. & Amyes, S. G. B. (1991). Transferable resistance to extended-spectrum β-lactams: a major threat or a minor inconvenience? Journal of Antimicrobial Chemotherapy 27, 255-61.
2. Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T. & Tenover, F. C. (1997). Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy 40, 135-6.
3. CDC. (1997). Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbidity and Mortality Weekly Report 46, 765-6.
4. Ploy, M. C., Grelaud, C., Martin, C., de Lumley, L. & Denis, F. (1998). First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351, 1212.
5. Anonymous. (1997). Detecting vancomycin intermediate Staphylococcus aureus. Communicable Disease Report. CDR Weekly 47, 417-20.
6. CDC. (1997). Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. Morbidity and Mortality Weekly Report 46, 626-8.
7. Tenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A. et al. (1998). Characterization of staphylococci with reduced susceptibility to vancomycin and other glycopeptides. Antimicrobial Agents and Chemotherapy 36, 1020-7.
8. Speller, D. C. E., Johnson, A. P., James, D., Marples, R. R., Charlett, A. & George, R. C. (1997). Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-95. Lancet 350, 323-5.
9. Johnson, A. P. & James, D. (1997). Continuing increase in invasive methicillin-resistant infection. Lancet 350, 1710.
10. Steinberg, J. P., Clark, C. C. & Hackman, B. O. (1996). Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clinical Infectious Diseases 23, 255-9.
11. Woodford, N., Johnson, A. P., Morrison, D. & Speller, D. C. E. (1995). Current perspectives on glycopeptide resistance. Clinical Microbiology Reviews 8, 585-615.
12. Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S. et al. (1997). Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350, 1670-3.
13. Felmingham, D. (1997). Glycopeptides. In Antibiotic and Chemotherapy, 7th edn (O'Grady, F., Lambert, H. P., Finch, R. G. & Greenwood, D., Eds), pp. 363-70. Churchill Livingstone, Edinburgh.
14. Torres, J. R., Sanders, C. V. & Lewis, A. C. (1979). Vancomycin concentration in human tissues - preliminary report. Journal of Antimicrobial Chemotherapy 5, 475-7.
15. Brunet, F., Vedel, G., Dreyfus, F., Vaxelaire, J. F., Giraud, T., Schremmer, B. et al. (1990). Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. European Journal of Clinical Microbiology and Infectious Diseases 9, 145-7.
16. Kaatz, G. W., Seo, S. M., Dorman, N. J. & Lerner, A. L. (1990). Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. Journal of Infectious Diseases 162, 103-8.
17. Fitch, L. & Johnson, A. P. (1998). Reduced susceptibility to teicoplanin in a methicillin-resistant strain of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 41, 578.
18. Vedel, G., Leruez, M., Lemann, F., Hraoui, E. & Ratovohery, D. (1990). Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs. European Journal of Clinical Microbiology and Infectious Diseases 9, 820-2.
19. Hospital Infection Control Practices Advisory Committee (HICPAC). (1995). Recommendations for preventing the spread of vancomycin resistance. Infection Control and Hospital Epidemiology 16, 105-13.